Menopause & HRT Glossary

503A compounding refers to traditional pharmacy compounding for individual patient prescriptions, regulated under section 503A of the FDA Modernization Act. 503A pharmacies prepare patient-specific medications and are state-board-regulated, not FDA-approved. Most compounded HRT is 503A-compounded.

ACOG is the principal professional association of obstetricians and gynecologists in the United States. It publishes practice bulletins, committee opinions, and clinical guidance on menopause, GSM, vaginal estrogen, hysterectomy decisions, and related topics that shape standard-of-care expectations in OB-GYN practice.

Allopregnanolone is a neurosteroid produced when the body metabolizes progesterone. It is a positive allosteric modulator of the GABA-A receptor — the same receptor targeted by benzodiazepines and alcohol — which is why bedtime oral micronized progesterone produces calming and sleep-promoting effects beyond its uterine-protective role.

AMH is a hormone produced by the granulosa cells of small ovarian follicles. AMH levels reflect ovarian reserve — the pool of remaining eggs — and decline progressively with age. AMH is most often used in fertility evaluation, but very low or undetectable AMH supports a diagnosis of imminent or completed menopause.

Androgens are a class of steroid hormones — including testosterone, dihydrotestosterone, androstenedione, and DHEA — that drive male secondary sex characteristics and are produced in smaller amounts in women. In women, androgens contribute to libido, muscle mass, and energy, and they serve as precursors that aromatase converts to estrogens.

The androgen receptor (AR) is a nuclear hormone receptor that binds testosterone and dihydrotestosterone (DHT) to mediate androgenic effects. AR is widely expressed including in muscle, bone, skin, brain, and reproductive tissues. SERMs and SERDs have analogs in the androgen-receptor world (e.g., spironolactone as antiandrogen).

Anovulation is the failure of an ovarian follicle to release an egg during a menstrual cycle. Anovulatory cycles produce unopposed estrogen exposure (no luteal-phase progesterone) and are common in perimenopause as well as in conditions like PCOS.

Aromatase is the enzyme (CYP19A1) that converts androgens — testosterone and androstenedione — into estrogens, estradiol and estrone respectively. After menopause, aromatase activity in adipose tissue is the main source of circulating estrogen. Aromatase inhibitors are used in breast cancer treatment and create a more profound estrogen-deprived state than menopause alone.

Aromatase inhibitors — anastrozole, letrozole, exemestane — block the aromatase enzyme that converts androgens to estrogens, reducing circulating estrogen to very low levels. They are first-line adjuvant therapy for hormone-receptor-positive breast cancer in postmenopausal women and produce severe menopause-like symptoms.

Asynchronous telehealth is healthcare delivery where the patient and clinician interact through structured questionnaires, secure messaging, and uploaded information rather than real-time video or in-person visits. It is widely used for non-controlled prescriptions including HRT, allowing 24-hour turnaround without scheduled appointments.

AUC is the area under the plasma concentration-vs-time curve for a drug, representing total drug exposure over a dosing interval. AUC is used in pharmacokinetic studies to compare formulations and routes; bioequivalence determinations rely on AUC and Cmax falling within acceptable ranges.

503B outsourcing facilities are larger compounding entities, regulated by the FDA under cGMP standards similar to drug manufacturers. They can compound without patient-specific prescriptions and supply hospitals and clinics. 503B compounding is more tightly regulated than 503A but still does not produce FDA-approved drugs.

Bioavailability is the fraction of an administered drug that reaches systemic circulation. Oral estradiol has low bioavailability (around 5%) due to extensive first-pass metabolism. Transdermal estradiol has bioavailability close to 100% because it bypasses first-pass metabolism.

Bioidentical hormones are hormones whose molecular structure is identical to those produced by the human body — primarily estradiol and progesterone in the menopause context. Bioidentical does not mean compounded; many FDA-approved estradiol and micronized progesterone products are bioidentical. It also does not automatically mean safer.

Bisphosphonates are a class of bone-active medications — alendronate, risedronate, ibandronate, zoledronic acid — that bind bone hydroxyapatite and reduce osteoclast-mediated bone resorption. They are first-line pharmacologic treatment for postmenopausal osteoporosis and reduce fracture risk by 30–50%.

Black cohosh (Actaea racemosa) is a botanical supplement widely used for vasomotor symptoms. Evidence for efficacy is mixed; some randomized trials show modest hot flash reduction, others show no benefit over placebo. Liver toxicity has been reported in rare cases.

Menopausal brain fog is a cluster of cognitive symptoms — word-finding difficulty, forgetfulness, slower processing, reduced concentration — common in perimenopause and early postmenopause. It reflects estrogen's direct effects on memory and attention systems, plus the indirect effects of poor sleep, hot flashes, and mood. Most women recover within a few years post-menopause.

BRCA1 and BRCA2 are tumor suppressor genes; mutations confer substantially elevated lifetime risks of breast and ovarian cancer. BRCA carriers face complex menopause decisions, including risk-reducing bilateral salpingo-oophorectomy that produces surgical menopause and the question of whether HRT is appropriate.

The relationship between HRT and breast cancer is more nuanced than the 2002 WHI headlines suggested. Oral conjugated equine estrogens plus medroxyprogesterone for 5+ years showed a small increase in breast cancer incidence; estrogen alone (in women without a uterus) showed a reduction. Modern transdermal estradiol plus bioidentical micronized progesterone appears to have a smaller signal, particularly in the first 5 years.

Breast cancer survivors, particularly those with HR-positive disease, often have severe menopausal symptoms — partly from chemotherapy-induced or natural menopause and partly from endocrine therapy (tamoxifen, aromatase inhibitors). Treatment options include non-hormonal medications, low-dose vaginal estrogen with oncology team input, and lifestyle measures.

Bremelanotide is an as-needed subcutaneous injection FDA-approved in 2019 for premenopausal hypoactive sexual desire disorder. It is a melanocortin-4 receptor agonist used 45 minutes before anticipated sexual activity. Common side effects include nausea, headache, and transient hypertension.

Calcium is the principal mineral in bone, with adequate intake essential for bone health. Postmenopausal women should aim for 1000–1200 mg daily, preferentially from food sources. Excess supplemental calcium has been associated with cardiovascular and kidney stone risks in some studies.

Cardiovascular disease risk rises after menopause as estrogen-deprived lipid profiles worsen and visceral adiposity increases. The timing hypothesis suggests HRT initiated within 10 years of menopause may have neutral-to-favorable cardiovascular effects, while later initiation has a less favorable profile.

Chemical menopause, also called induced menopause, is iatrogenic loss of ovarian function from chemotherapy, pelvic radiation, or GnRH agonist therapy (e.g., leuprolide). It can be temporary or permanent depending on the agent, dose, and the patient's age and ovarian reserve. Symptoms can be as severe as surgical menopause.

Clonidine is a centrally-acting alpha-2 adrenergic agonist originally developed for hypertension. It has modest efficacy for hot flashes (roughly 15–30% reduction) and is rarely first-line, but remains an option for women who cannot use estrogen, SSRIs/SNRIs, or fezolinetant.

Cmax is the peak plasma concentration of a drug after dosing. Cmax matters for both efficacy and side effects — high Cmax can drive transient adverse effects, while low Cmax may indicate inadequate absorption. Sustained-release formulations smooth Cmax to provide steadier levels.

Cognitive Behavioral Therapy (CBT) is a structured, evidence-based psychotherapy that targets thoughts, behaviors, and emotional responses. CBT for menopause symptoms (CBT-Meno) and for insomnia (CBT-I) have randomized-trial evidence for reducing hot flash bother, mood symptoms, and sleep disruption.

Collagen content in skin and connective tissues declines progressively with age and accelerates after menopause — approximately 30% loss in the first 5 years post-menopause. This contributes to skin thinning, joint laxity, and accelerated bone loss. Estrogen replacement modestly improves skin collagen content.

Combination HRT is hormone therapy that includes both estrogen and a progestogen (progesterone or progestin). It is the standard regimen for women with an intact uterus, where progestogen is required to protect the endometrium from estrogen-driven hyperplasia. Combination can be delivered as separate products or as combined patches/tablets.

Compounded HRT is hormone therapy mixed by a licensed pharmacy specifically for one patient, typically combining bioidentical estradiol and progesterone in a custom dose, ratio, or vehicle. Compounded HRT is not FDA-tested for batch consistency. It is appropriate when no FDA-approved product fits a patient's clinical need.

Cortisol is the primary glucocorticoid hormone, produced by the adrenal cortex in response to ACTH from the pituitary. It regulates blood glucose, immune response, and stress reactivity. Cortisol interacts with menopausal physiology — chronic stress and disrupted sleep can amplify menopausal symptoms, and cortisol rhythms shift across the menopause transition.

Cytochrome P450 enzymes are a large family of liver enzymes that metabolize most prescription drugs and steroid hormones. CYP3A4 is the most clinically important for HRT; inhibitors and inducers of CYP3A4 can alter circulating estrogen levels. CYP2D6 affects tamoxifen metabolism, with implications for hot-flash drug choice in tamoxifen patients.

Denosumab is a monoclonal antibody against RANKL that potently inhibits osteoclast formation and activity. It is given as a subcutaneous injection every 6 months for postmenopausal osteoporosis and reduces fracture risk substantially. Stopping denosumab without follow-on therapy causes rapid bone density loss and rebound vertebral fractures.

DEXA is the gold-standard imaging test for bone mineral density. A DEXA scan measures bone density at the hip and lumbar spine, generating T-scores (versus young-adult mean) and Z-scores (versus age-matched mean). T-score ≤ -2.5 defines osteoporosis; -1.0 to -2.5 defines osteopenia. Postmenopausal women should have a baseline DEXA at 65, or earlier if risk factors are present.

DHEA is a steroid prohormone produced primarily by the adrenal glands. It serves as a precursor to both androgens and estrogens. DHEA levels peak around age 20–30 and decline progressively with age. The intravaginal form (prasterone, sold as Intrarosa) is FDA-approved for moderate-to-severe dyspareunia from menopausal vaginal atrophy.

Drospirenone is a fourth-generation progestin with antiandrogenic and antimineralocorticoid activity. It is the progestin in the combination HRT product Angeliq (estradiol + drospirenone) and in several oral contraceptives. It carries a slightly higher VTE risk than older progestins.

Duavee combines conjugated equine estrogens with the SERM bazedoxifene as a tissue-selective estrogen complex. The bazedoxifene component provides endometrial protection without traditional progestogen. It is FDA-approved for vasomotor symptoms and osteoporosis prevention in women with an intact uterus.

Deep vein thrombosis is a blood clot in the deep veins, most often in the legs. Symptoms include unilateral leg swelling, pain, warmth, and erythema. DVT can embolize to cause pulmonary embolism. Oral estrogen modestly raises DVT risk; transdermal estrogen does not.

Dyspareunia is the medical term for painful sexual intercourse. In menopausal women it is most commonly caused by genitourinary syndrome of menopause — vaginal atrophy, dryness, and reduced lubrication. Treatment with vaginal estrogen, intravaginal DHEA, or oral ospemifene typically resolves it within 6–12 weeks.

Early menopause is menopause that occurs between ages 40 and 45 — earlier than the typical median age of 51, but not as early as primary ovarian insufficiency (before 40). Women with early menopause typically need hormone therapy at least until the average age of menopause to protect bone, cardiovascular, and cognitive health.

ELITE was a randomized trial that tested whether oral estradiol's effect on atherosclerosis progression depended on time-since-menopause. It found that women starting estradiol within 6 years of menopause had slower carotid intima-media thickening than placebo, while women 10+ years post-menopause did not — strong support for the timing hypothesis.

The Endocrine Society is the principal global professional society for endocrinology, publishing clinical practice guidelines on menopause hormone therapy, female sexual dysfunction, and related endocrine topics. Its menopause guidance generally aligns with NAMS while emphasizing the endocrinologist's perspective on broader hormonal balance.

Endometrial cancer is malignancy of the uterine lining. Unopposed estrogen is a major risk factor — which is why women with a uterus on systemic estrogen require progestogen for endometrial protection. Properly combined HRT does not raise endometrial cancer risk over baseline.

Endometriosis is a condition in which endometrial-like tissue grows outside the uterus, causing inflammation, pain, and infertility. It is estrogen-dependent and typically improves after menopause, though some women have persistent symptoms. HRT can occasionally reactivate endometriosis lesions, requiring careful management.

The endometrium is the inner lining of the uterus that proliferates and sheds cyclically during the reproductive years. Estrogen drives proliferation; progesterone produces the secretory phase. In HRT, unopposed estrogen overstimulates the endometrium and raises endometrial cancer risk, which is why progesterone is required in women with a uterus.

Estradiol (E2) is the primary estrogen produced by the ovaries during the reproductive years and the most biologically active of the three human estrogens. It supports brain, bone, cardiovascular, skin, and urogenital function. Almost every modern hormone replacement therapy product — patches, gels, sprays, vaginal preparations — uses estradiol because it is bioidentical to what the body produced for decades.

Estradiol gel is a transdermal estradiol formulation applied daily to the skin (arm or thigh). Like patches, it bypasses first-pass hepatic metabolism. It allows finer dose adjustments than patches and may be a better option for women with skin sensitivity to patch adhesives.

Transdermal estradiol patches deliver estradiol through the skin at a steady rate, typically replaced once or twice weekly. Doses range from 0.025 mg/day to 0.1 mg/day. Patches bypass first-pass hepatic metabolism, which avoids the modest increase in venous thromboembolism risk associated with oral estrogen, making them a preferred first-line systemic estrogen for many menopausal women.

Estradiol spray (Evamist) delivers a metered dose of estradiol through the skin once daily on the inner forearm. Like other transdermal options, it bypasses first-pass hepatic metabolism. It is one of the lowest-profile transdermal options.

Estring is a soft silicone vaginal ring that releases approximately 7.5 mcg of estradiol per day for 90 days. It is placed in the vagina and changed every 3 months. Estring is one of the most convenient vaginal estrogen options — most women cannot feel it and rarely think about it once placed.

Estriol (E3) is the weakest of the three human estrogens and is produced in large amounts only during pregnancy by the placenta. It is not part of standard FDA-approved hormone replacement therapy in the United States, although it is used in some compounded "Bi-est" preparations and is approved for menopause use in parts of Europe.

Estrogen is the umbrella name for a family of steroid sex hormones that includes estradiol (E2), estrone (E1), and estriol (E3). In premenopausal women the dominant estrogen is estradiol, produced by the ovaries; after menopause estrone produced from adipose tissue dominates. Estrogen receptors exist throughout the body and influence brain, bone, vascular, and reproductive tissue.

Estrogen receptors are the cellular proteins that bind estrogen and mediate its effects. The two main nuclear estrogen receptors are ERα (encoded by ESR1) and ERβ (encoded by ESR2); the membrane-bound G protein-coupled estrogen receptor (GPER) mediates rapid non-genomic signaling.

Estrogen receptor alpha (ERα) is one of two main nuclear estrogen receptors. It is highly expressed in uterus, breast, ovary, liver, hypothalamus, and bone, and mediates much of estrogen's effect on reproductive tissues, bone density, lipid metabolism, and vasomotor regulation.

Estrogen receptor beta (ERβ) is the second of the two main nuclear estrogen receptors. It is expressed in brain, ovary, prostate, lung, GI tract, immune cells, and vascular endothelium. ERβ generally counterbalances ERα-mediated proliferative effects and contributes to the central nervous system effects of estrogen.

Estrogen-only HRT is hormone therapy with estrogen alone, without a progestogen. It is appropriate only for women without a uterus — typically after hysterectomy. Without progestogen protection, estrogen overgrows the endometrium and substantially raises endometrial cancer risk, so estrogen-only HRT is contraindicated in women with an intact uterus.

Estrone (E1) is the dominant estrogen after menopause, produced mainly by the conversion of androstenedione to estrone in fat tissue rather than by the ovaries. It is roughly one-tenth as biologically active as estradiol at the estrogen receptor and does not adequately replace estradiol's role in brain, bone, and vascular tissue.

FDA-approved HRT refers to hormone therapy products mass-produced by drug manufacturers and approved by the FDA — patches, gels, sprays, tablets, vaginal preparations, and rings. Each batch is tested for dose accuracy and stability. ClearedRx prescribes FDA-approved HRT as the default and uses compounded preparations only when clinically warranted.

Female sexual dysfunction encompasses persistent problems with sexual desire, arousal, orgasm, or pain that cause personal distress. Menopause-related causes include genitourinary syndrome (dryness, dyspareunia), declining androgen levels, and the secondary effects of poor sleep and mood. Treatment is targeted to the dominant mechanism.

Femring is an estradiol vaginal ring that delivers systemic doses (0.05 or 0.1 mg of estradiol per day) for 90 days. Unlike the lower-dose Estring, Femring is FDA-approved for systemic use to treat vasomotor symptoms and requires progesterone in women with a uterus.

Fezolinetant is a non-hormonal oral medication FDA-approved in 2023 for moderate-to-severe vasomotor symptoms. It blocks the neurokinin-3 (NK3) receptor on KNDy neurons in the hypothalamus — the same neural circuit that is dysregulated by estrogen withdrawal — and reduces hot flash frequency and severity within weeks.

First-pass metabolism is the metabolism of an orally absorbed drug by the gut and liver before it reaches systemic circulation. For oral estradiol, first-pass conversion to estrone in the liver and gut reduces circulating estradiol and stimulates hepatic synthesis of clotting factors and SHBG — which is why transdermal estrogen has a more favorable VTE profile than oral.

Flibanserin is a once-daily 100 mg oral medication FDA-approved in 2015 for premenopausal hypoactive sexual desire disorder. It modulates serotonin, dopamine, and norepinephrine signaling. Effects are modest and it must not be combined with alcohol.

The final menstrual period (FMP) is the very last menstrual bleed in a woman's life. It can only be identified retrospectively, after 12 consecutive months without a period. Median age of FMP in the United States is 51. The FMP is the technical anchor for the date of menopause.

FRAX is a clinical tool that estimates an individual's 10-year risk of major osteoporotic fracture (hip, spine, forearm, shoulder) and 10-year hip fracture risk. It combines age, sex, BMI, country, fracture history, parental hip fracture, smoking, alcohol, glucocorticoid use, rheumatoid arthritis, secondary osteoporosis, and DEXA femoral neck T-score. Results guide treatment decisions in osteopenia.

The FSDS-R is a 13-item validated instrument that measures personal distress related to sexual function. It is used to confirm clinically significant distress as part of diagnosing female sexual dysfunction, including hypoactive sexual desire disorder.

FSH is a glycoprotein hormone produced by the anterior pituitary that stimulates ovarian follicle growth and estradiol production. As ovarian reserve declines, the pituitary releases more FSH in an attempt to recruit follicles, so postmenopausal FSH typically rises above 30 mIU/mL. FSH is unreliable for diagnosing perimenopause because levels swing widely cycle to cycle.

Fulvestrant is an injectable selective estrogen receptor degrader (SERD) used to treat hormone-receptor-positive advanced breast cancer. It binds the estrogen receptor and triggers its proteasomal degradation, producing a more complete antiestrogenic effect than SERMs.

The GABA-A receptor is a ligand-gated chloride channel that mediates the brain's primary inhibitory neurotransmission. It is the target of benzodiazepines, alcohol, barbiturates, and the progesterone metabolite allopregnanolone — which is why bedtime oral micronized progesterone produces a calming, sleep-promoting effect.

Gabapentin is an anticonvulsant used off-label for hot flashes, particularly nighttime hot flashes that disrupt sleep. Bedtime dosing of 300–900 mg can reduce hot flash frequency and improve sleep, making it a useful non-hormonal option for women whose primary complaint is night sweats.

GnRH is a hypothalamic peptide hormone that stimulates the pituitary to release FSH and LH. GnRH agonists (like leuprolide) are used to suppress the hypothalamic-pituitary-ovarian axis in conditions such as endometriosis and breast cancer; they cause an iatrogenic, reversible menopause-like state.

GPER is a membrane-bound estrogen receptor (also called GPR30) that mediates rapid, non-genomic effects of estrogen. It contributes to vascular, neural, and immune actions of estrogen and is an active area of research for menopause, cardiovascular disease, and cancer.

The Greene Climacteric Scale is a 21-item self-report instrument that measures menopausal symptoms across psychological, somatic, vasomotor, and sexual domains. It is one of the older standardized symptom scales and is still used in research and some clinical settings, though the MRS and MENQOL are more common in modern practice.

Genitourinary syndrome of menopause (GSM) is the constellation of symptoms — vaginal dryness, burning, painful sex, urinary urgency, and recurrent urinary tract infections — caused by estrogen withdrawal's effects on vulvovaginal and lower urinary tract tissues. Unlike hot flashes, GSM is progressive and does not improve without treatment. Vaginal estrogen reverses it directly.

The half-life of a drug is the time required for its plasma concentration to fall by 50%. Estradiol's plasma half-life is short (1–3 hours) — which is why transdermal patches release continuously rather than once-daily oral dosing. Half-life governs dosing frequency and time to steady state.

Hepatic metabolism is the processing of drugs and hormones by the liver, primarily through cytochrome P450 (phase I) and conjugation (phase II) enzymes. Oral estrogens undergo extensive hepatic metabolism, which produces both first-pass loss of active drug and the hepatic protein-synthesis effects responsible for elevated VTE risk.

Hot flashes are sudden episodes of intense heat, flushing, and sweating, often followed by chills. They result from estrogen withdrawal narrowing the brain's thermoneutral zone, making minor temperature changes trigger a cooling response. Hot flashes affect up to 80% of women, can last 7–10 years on average, and respond well to hormone therapy (75–90% reduction).

The hypothalamic-pituitary-ovarian (HPO) axis is the hormonal control system that regulates female reproduction. The hypothalamus releases GnRH, the pituitary releases FSH and LH, and the ovaries produce estradiol and progesterone. Menopause is fundamentally the failure of the ovarian end of this axis.

Hormone replacement therapy (HRT) is the prescription replacement of estrogen — and, for women with a uterus, progesterone — to relieve menopausal symptoms and protect long-term bone, vascular, and cognitive health. Modern HRT typically uses bioidentical transdermal estradiol plus oral or vaginal micronized progesterone. The newer term is menopausal hormone therapy (MHT).

Hypoactive sexual desire disorder is persistently low or absent sexual desire that causes personal distress. It is the most common female sexual dysfunction and is more prevalent after menopause. Evidence-based treatments include low-dose testosterone (off-label in the US), flibanserin, and bremelanotide.

The hypothalamus is a small region at the base of the brain that controls autonomic function, hormonal regulation through the pituitary, body temperature, sleep, and many other homeostatic processes. Estrogen-sensitive hypothalamic neurons regulate thermoregulation, GnRH pulsatility, and feedback control of the reproductive axis.

Hypothyroidism is underactive thyroid function, marked by elevated TSH and (in overt cases) low free T4. Symptoms — fatigue, weight gain, cold intolerance, dry skin, constipation, brain fog, depression — overlap heavily with menopausal symptoms. Hypothyroidism is common in midlife women and should be screened with TSH at any menopause workup.

Hysterectomy is surgical removal of the uterus, performed for benign indications (fibroids, abnormal bleeding, prolapse, endometriosis) or malignant indications (uterine, cervical, ovarian cancer). After hysterectomy without ovarian removal, menopause occurs naturally on its usual timeline; with bilateral oophorectomy, menopause begins immediately.

The International Menopause Society (IMS) is the global menopause specialist society, with member societies on every continent. It produces the IMS Recommendations on Menopausal Hormone Therapy and the journal Climacteric, and serves as the international counterpart to NAMS.

Imvexxy is a small soft estradiol vaginal insert delivering 4 or 10 mcg of estradiol, placed twice weekly. It is one of the lowest-dose vaginal estrogen options and is inserted with the finger — no applicator, no leakage. It is a clean, convenient option for genitourinary syndrome of menopause.

Inhibin B is a glycoprotein produced by ovarian granulosa cells that suppresses pituitary FSH release. Inhibin B levels fall as ovarian reserve declines, contributing to the rise in FSH that defines the menopause transition. It is occasionally used in research and reproductive endocrinology but is not part of routine menopause workup.

Insulin resistance is reduced cellular response to insulin, requiring higher insulin levels to maintain normal blood glucose. It worsens through midlife and after menopause, contributing to metabolic syndrome, type 2 diabetes risk, and abdominal weight gain. HRT may modestly improve insulin sensitivity.

Isoflavones are phytoestrogens found primarily in soy and red clover, with the major dietary forms being genistein and daidzein. They bind estrogen receptors with low affinity and have been studied for menopausal symptoms with mixed results — modest hot-flash reduction in some trials.

KEEPS was a randomized trial of low-dose oral conjugated estrogens or transdermal estradiol versus placebo in women aged 42–58 within 3 years of menopause. It found no significant difference in atherosclerosis progression but favorable effects on symptoms, lipids, mood, and bone — supporting the timing hypothesis for HRT in younger postmenopausal women.

KNDy neurons are hypothalamic neurons that co-express kisspeptin, neurokinin B, and dynorphin. They regulate GnRH pulsatility and contribute to thermoregulation. Estrogen withdrawal at menopause leads to KNDy neuron hypertrophy and excessive neurokinin B signaling, dysregulating the thermoneutral zone — the basis for fezolinetant's mechanism.

Leuprolide is a GnRH agonist used to suppress the hypothalamic-pituitary-ovarian axis in conditions including endometriosis, fibroids, breast cancer, and central precocious puberty. Continuous administration downregulates GnRH receptors and produces a reversible chemical menopause-like state.

The 52-mg levonorgestrel-releasing intrauterine device (Mirena, Liletta) provides excellent endometrial protection in women on systemic estrogen and is FDA-approved for this off-label use in some markets. It is particularly useful for women who do not want a daily oral progestogen or who have heavy bleeding in perimenopause.

Levothyroxine is synthetic T4 used to treat hypothyroidism. It is dosed once daily on an empty stomach (or per consistent timing) and titrated against TSH every 6–8 weeks until stable. It is one of the most-prescribed drugs in the United States.

LH is a pituitary hormone that triggers ovulation mid-cycle and stimulates the corpus luteum to produce progesterone. After menopause, with no follicles to ovulate, LH stays elevated. Like FSH, LH is generally not required for diagnosing menopause when symptoms and cycle history are clear.

Libido is sexual drive — the spontaneous interest in sexual activity. Libido is influenced by hormonal factors (estrogen, testosterone, prolactin, thyroid), psychological factors (mood, stress, relationship satisfaction), and medications. It typically declines through the menopause transition for both hormonal and contextual reasons.

Lichen sclerosus is a chronic inflammatory skin condition that most commonly affects the vulva and perianal area. It causes intense itching, white atrophic patches, fissuring, and architectural changes including labial resorption. It is more common in postmenopausal women and is often misdiagnosed as menopausal vaginal atrophy. Treatment is high-potency topical corticosteroids, not estrogen.

Lifestyle measures that improve menopause symptoms and long-term health include resistance training, adequate dietary protein (1.0–1.6 g/kg/day), Mediterranean dietary patterns, sleep hygiene, alcohol moderation, smoking cessation, and stress management. These foundations apply whether or not a woman uses HRT.

Mammography is the primary breast cancer screening modality. USPSTF recommends biennial screening for women aged 40–74 (updated 2024 from prior 50–74). HRT users should continue routine mammographic screening; HRT does not change screening intervals.

Medroxyprogesterone acetate (MPA) is the synthetic progestin used in the WHI estrogen-plus-progestin arm. It is effective for endometrial protection but has been associated in observational and randomized data with a higher breast cancer signal than bioidentical micronized progesterone, leading many modern HRT practices to prefer micronized progesterone.

Joint pain — particularly in the hands, knees, and hips — is a common menopause symptom often called "menopausal arthralgia." Estrogen withdrawal contributes to joint inflammation and altered cartilage metabolism. Women on aromatase inhibitors experience more severe arthralgia.

Migraine patterns commonly change across the menopause transition. Many women with menstrual migraine see improvement after menopause, but some women experience worsening or new-onset migraine in perimenopause due to estrogen fluctuation. Migraine with aura is generally a contraindication to high-dose oral combined hormonal contraceptives.

Heart palpitations — sensations of skipped beats, fluttering, or pounding heart — are a common menopause symptom often associated with hot flashes, anxiety, or sleep disruption. Most are benign, but new palpitations in midlife warrant cardiac evaluation to rule out arrhythmia.

Menopause is the point in time defined as 12 consecutive months without a menstrual period, marking the end of ovarian reproductive function. The average age in the United States is 51. Menopause is a single point in time; the years of symptomatic hormonal change before it are perimenopause, and the years after are postmenopause.

Hair changes in menopause include thinning of scalp hair (female pattern hair loss accelerating in midlife), changes in texture and luster, and increased facial hair due to a relative shift in androgen-to-estrogen ratio. Treatment options include topical minoxidil, oral spironolactone, and addressing underlying iron and thyroid issues.

Menopause insomnia describes the constellation of sleep disturbances that emerge during the menopause transition: difficulty falling asleep, frequent night-time waking (especially around 3 AM), and non-restorative sleep. Causes are multifactorial — night sweats, estrogen withdrawal's direct effect on sleep architecture, anxiety, and falling progesterone all contribute.

The Menopause Rating Scale is a validated 11-item self-assessment tool for menopausal symptom severity. It scores symptoms across somatic, psychological, and urogenital domains on a 0–4 severity scale, producing a total score that classifies symptom burden as none, mild, moderate, or severe. ClearedRx uses the MRS in its Symptom Score tool.

Skin changes in menopause include accelerated thinning, reduced collagen content (up to 30% loss in the first 5 years post-menopause), increased dryness, reduced elasticity, and slower wound healing. Estrogen replacement modestly improves skin thickness and collagen content.

A menopause symptom score is a brief self-assessment tool that quantifies symptom burden across multiple domains. ClearedRx uses an MRS-based 11-item Symptom Score to give patients a severity tier (none, mild, moderate, severe) and inform treatment recommendations.

Weight gain — particularly abdominal/visceral fat accumulation — is common across the menopause transition. Mechanisms include estrogen withdrawal's effect on fat distribution, age-related decline in muscle mass and resting metabolic rate, sleep disruption, and lifestyle factors. HRT does not reliably cause weight gain but does shift fat distribution back toward a more premenopausal pattern.

The Menopause-Specific Quality of Life questionnaire (MENQOL) is a 29-item validated instrument that measures quality-of-life impact across vasomotor, psychosocial, physical, and sexual domains. It is widely used in clinical trials of menopausal therapies.

Metabolic syndrome is a cluster of cardiovascular and diabetes risk factors — abdominal obesity, hypertension, dyslipidemia, and insulin resistance — that often emerges or worsens after menopause. Estrogen withdrawal contributes to lipid changes and visceral adiposity, raising postmenopausal women's metabolic risk toward male levels.

Menopausal hormone therapy (MHT) is the contemporary preferred term for hormone replacement therapy. NAMS and other professional societies adopted MHT to emphasize that the goal is appropriate hormonal support during a life stage rather than "replacing" what was lost. MHT and HRT refer to the same treatment.

Micronized progesterone is bioidentical progesterone whose particle size has been reduced to improve oral absorption. The FDA-approved brand is Prometrium; generics are widely available. Bedtime dosing produces both endometrial protection and a sleep-promoting effect via the allopregnanolone metabolite.

Minoxidil is a vasodilator originally developed for hypertension, now used topically for hair regrowth. Topical minoxidil 5% is FDA-approved for female pattern hair loss; oral low-dose minoxidil is increasingly used off-label for the same indication.

Mood changes — irritability, anxiety, low mood, emotional reactivity — are common in perimenopause and early postmenopause. Mechanisms include estrogen withdrawal's effect on serotonin and norepinephrine signaling, sleep disruption from night sweats, and cumulative life-stage stressors. Treatment options range from HRT to SSRIs/SNRIs to CBT, often in combination.

The Million Women Study is a large UK observational cohort study of more than a million postmenopausal women that has reported on HRT and breast, ovarian, and other cancer risks. It contributed to the post-WHI concern about HRT and breast cancer but, as an observational study, has limitations including non-randomization and recall bias.

The myometrium is the muscular wall of the uterus, composed of smooth muscle. It produces menstrual cramping, labor contractions, and is the tissue affected by uterine fibroids (leiomyomas). Estrogen is a major growth factor for myometrium and fibroids.

NAMS — formerly the North American Menopause Society, now branded as The Menopause Society — is the leading professional society for menopause clinicians in North America. Its position statements (notably the 2022 Hormone Therapy Position Statement) are the most-cited evidence-based guidance on HRT in the United States.

Night sweats are vasomotor symptoms — hot flashes — that occur during sleep, often drenching nightclothes and bedding and frequently waking the woman. They fragment sleep and are a major contributor to menopausal insomnia, fatigue, and cognitive complaints. Night sweats respond reliably to estradiol within 2–4 weeks.

NK3 receptor antagonists block the neurokinin-3 receptor in hypothalamic thermoregulatory neurons. By interrupting the excessive neurokinin B signaling that drives vasomotor symptoms after estrogen withdrawal, NK3 antagonists like fezolinetant reduce hot flashes without altering estrogen levels.

Norethindrone (also called norethisterone) is a 19-nortestosterone-derived progestin used for endometrial protection in HRT (notably as the progestin in the Combipatch and Climara Pro combined patches) and as the progestogen in many oral contraceptives.

Oophorectomy is surgical removal of the ovaries. Bilateral oophorectomy (both ovaries) produces immediate surgical menopause regardless of age, with abrupt loss of estrogen, progesterone, and roughly half of circulating testosterone. Women under 45 who undergo bilateral oophorectomy almost always need HRT.

Oral HRT is hormone therapy taken as a swallowed tablet — typically estradiol, conjugated equine estrogens, or oral micronized progesterone. Oral estrogen undergoes first-pass hepatic metabolism, which raises SHBG, certain coagulation factors, and triglycerides, contributing to a small increase in venous thromboembolism risk compared to transdermal routes.

Ospemifene is an oral selective estrogen receptor modulator (SERM) FDA-approved for moderate-to-severe dyspareunia from menopause-related vulvovaginal atrophy. Unlike estrogen, it has tissue-selective effects — agonist on vaginal tissue, antagonist on breast — and is taken as a once-daily 60 mg pill.

Osteopenia is low bone mass that does not yet meet the threshold for osteoporosis — DEXA T-score between -1.0 and -2.5 at hip or spine. It is common in postmenopausal women and represents an opportunity to reduce future fracture risk through lifestyle, calcium and vitamin D, weight-bearing exercise, and sometimes medication.

Osteoporosis is a skeletal disease of low bone mass and disrupted bone microarchitecture, leading to fragility fractures. Postmenopausal estrogen deprivation accelerates bone loss for the first 5–7 years after the final menstrual period. HRT, bisphosphonates, denosumab, and other therapies all reduce fracture risk.

Long-term HRT use (>5–10 years) has been associated with a small absolute increase in ovarian cancer incidence in some observational studies. Absolute risk remains low. Most modern menopause societies discuss this as a small risk to weigh against benefits, particularly for women considering long-duration HRT.

Ovarian reserve refers to the remaining quantity and quality of a woman's eggs (oocytes). It declines progressively with age and predicts time-to-menopause and fertility potential. AMH and antral follicle count on ultrasound are the primary clinical measures.

The ovary is the female gonad, paired and located in the pelvis. It produces eggs (ova) and the principal female sex hormones — estradiol, progesterone, and small amounts of testosterone. Ovarian function declines progressively from age 35 onward and essentially stops at menopause.

Ovulation is the release of a mature egg from the ovary, typically occurring around day 14 of a 28-day menstrual cycle. The mid-cycle LH surge triggers ovulation. Anovulatory cycles become more common in late perimenopause as ovarian reserve declines.

Oxybutynin is an anticholinergic medication FDA-approved for overactive bladder. It has also been studied for vasomotor symptoms and shows modest hot flash reduction (~25–35%). Cognitive side effects from anticholinergic burden limit long-term use in older women.

The Pap smear (cervical cytology) and HPV testing are the cornerstones of cervical cancer screening. USPSTF recommends screening for women aged 21–65 with various intervals depending on age and approach. Screening continues into the early postmenopausal years and may stop at 65 with adequate prior negative screening.

Paroxetine is a selective serotonin reuptake inhibitor (SSRI) approved at low dose (7.5 mg, branded Brisdelle) as a non-hormonal treatment for moderate-to-severe vasomotor symptoms. It reduces hot flash frequency by roughly 25–35% — less than HRT but useful for women who cannot take estrogen.

Polycystic ovary syndrome is a common endocrine disorder of reproductive-age women characterized by anovulation, androgen excess, and polycystic-appearing ovaries. PCOS continues to affect women through perimenopause and beyond, with cardiovascular and metabolic implications that influence menopause care.

Hormone pellets are compounded subcutaneous implants of estradiol and/or testosterone, inserted under the skin every 3–6 months. NAMS does not recommend hormone pellets — typical pellet doses produce supraphysiologic hormone levels far above what the body produced premenopausally, the dose cannot be adjusted once implanted, and there is no FDA-approved version.

Pelvic floor dysfunction is impaired function of the muscles, ligaments, and connective tissues that support the pelvic organs. It manifests as urinary or fecal incontinence, pelvic organ prolapse, sexual dysfunction, or chronic pelvic pain. Pelvic floor physical therapy is first-line treatment for most forms.

Pelvic organ prolapse is descent of the bladder, uterus, rectum, or vaginal apex from their normal positions through a weakened pelvic floor. It is more common after vaginal childbirth and in postmenopausal women. Treatment ranges from pelvic floor PT and pessaries to surgical repair, depending on severity and patient preference.

Perimenopause is the 4–10 year transition leading up to menopause, characterized by hormone fluctuations, irregular menstrual cycles, and the onset of vasomotor and mood symptoms. It typically begins in a woman's 40s and ends 12 months after the final menstrual period — the official date of menopause.

Phytoestrogens are plant-derived compounds — including isoflavones (soy, red clover), lignans (flaxseed), and coumestans — that bind estrogen receptors with low potency. Some women report symptom benefit from dietary phytoestrogens or supplements, but RCT evidence for vasomotor symptom reduction is mixed and effects are modest at best.

The pituitary gland is a pea-sized endocrine gland at the base of the brain that releases hormones controlling growth, reproduction, thyroid, adrenal, and water balance. The anterior pituitary releases FSH and LH that stimulate the ovary; in menopause, the ovary fails to respond and FSH/LH rise.

Primary ovarian insufficiency (POI), also called premature ovarian insufficiency, is loss of normal ovarian function before age 40. It is not just early symptoms — without estrogen, women with POI face higher long-term risks of osteoporosis, cardiovascular disease, and cognitive decline. HRT is essentially required at least until the average menopause age of 51.

Postmenopause is the phase of life after the final menstrual period — beginning 12 months after the last period and continuing indefinitely. Vasomotor symptoms often ease over time, but genitourinary syndrome typically progresses, and the long-term risks of bone loss, cardiovascular disease, and cognitive decline rise without estrogen.

Prasterone (Intrarosa) is an intravaginal DHEA insert FDA-approved for moderate-to-severe dyspareunia from menopause-related vulvovaginal atrophy. Vaginal cells convert DHEA locally to small amounts of estrogen and testosterone, treating GSM without raising serum estrogen.

Premarin is the original 1942 estrogen pill made from pregnant mare urine — a mixture of conjugated equine estrogens, not pure estradiol. Premarin works for menopausal symptoms and was the estrogen used in the WHI study. Most modern HRT now uses bioidentical estradiol, which more closely resembles what the body produced before menopause.

Progesterone is a steroid hormone produced by the corpus luteum of the ovary after ovulation, and by the placenta during pregnancy. In hormone replacement therapy, progesterone is added to estrogen for any patient with an intact uterus to protect the endometrium from estrogen-driven hyperplasia. Bedtime oral micronized progesterone also has sleep-promoting effects.

The progesterone receptor (PR) is a nuclear hormone receptor that binds progesterone and mediates its effects. Two main isoforms — PR-A and PR-B — have different tissue distributions and functions. PR is itself an estrogen-induced gene, which is why progesterone acts only effectively in tissues already exposed to estrogen.

Progestins are synthetic progesterone-like molecules — including medroxyprogesterone acetate, norethindrone, drospirenone, and levonorgestrel — used for endometrial protection in HRT and as the progestogen component in hormonal contraception. They are not bioidentical to progesterone and have varying side effect and safety profiles.

Prometrium is the FDA-approved oral micronized progesterone product — bioidentical progesterone in capsules of 100 mg or 200 mg. Taken at bedtime, it provides endometrial protection for women on estrogen and produces a calming, sleep-promoting effect through its allopregnanolone metabolite.

Pulmonary embolism is a blood clot — typically a fragment from a deep vein thrombosis — that lodges in a pulmonary artery, blocking blood flow. Symptoms include sudden shortness of breath, chest pain (often pleuritic), tachycardia, and in severe cases hemodynamic collapse. PE is the most serious VTE complication.

Raloxifene is a SERM FDA-approved for prevention and treatment of postmenopausal osteoporosis and for breast cancer risk reduction in postmenopausal women at high risk. It acts as an estrogen agonist on bone and an antagonist on breast and endometrium. It does not treat hot flashes.

Recurrent urinary tract infections (≥2 in 6 months or ≥3 in 12 months) are a common postmenopausal complication, driven by the same estrogen-deprived urethral and vaginal changes that cause GSM. Vaginal estrogen reduces UTI recurrence by roughly half and is one of the most evidence-supported uses of local hormone therapy.

Rapid eye movement (REM) sleep is the sleep stage characterized by vivid dreaming, rapid eye movements, and skeletal muscle paralysis. REM dominates the second half of a normal night and supports emotional processing and procedural memory. Estrogen withdrawal at menopause is associated with reduced REM time and density.

Route of administration is how a drug is delivered to the body — oral, transdermal, vaginal, intramuscular, subcutaneous, sublingual, or intrauterine. For HRT, route choice profoundly affects pharmacokinetics, side effects, and safety. Transdermal estradiol vs. oral estradiol is the most consequential route choice in modern HRT.

Sarcopenia is age-related loss of muscle mass and function. It begins in the 40s and accelerates after menopause, contributing to frailty, falls, metabolic dysfunction, and bone loss. Resistance training plus adequate protein intake (1.0–1.6 g/kg/day) is the foundational treatment.

SERDs are compounds that bind estrogen receptors and target them for proteasomal degradation, producing pure antiestrogenic effects without the partial agonism of SERMs. Fulvestrant is the FDA-approved injectable SERD for hormone-receptor-positive metastatic breast cancer; elacestrant is the first oral SERD.

SERMs are compounds that act as estrogen receptor agonists in some tissues and antagonists in others. Examples include tamoxifen (breast antagonist, uterine agonist), raloxifene (bone agonist, breast antagonist), and ospemifene (vaginal agonist, breast antagonist). SERMs allow tissue-selective benefits without full estrogen agonism.

SHBG is a liver-produced glycoprotein that binds testosterone, dihydrotestosterone, and estradiol in circulation, reducing their free (active) fraction. Oral estrogen substantially raises SHBG via first-pass hepatic stimulation; transdermal estrogen does not. Elevated SHBG can lower free testosterone and contribute to symptoms.

Obstructive sleep apnea is a condition in which the upper airway repeatedly collapses during sleep, causing intermittent oxygen drops and arousals. Prevalence rises sharply in women after menopause, and untreated sleep apnea mimics or worsens many menopausal symptoms — including fatigue, brain fog, and mood changes.

Sleep architecture refers to the structured pattern of sleep stages — N1, N2, N3 (slow-wave/deep sleep), and REM — across a typical night. Estrogen and progesterone both influence sleep architecture, and menopause is associated with reductions in slow-wave and REM sleep, contributing to non-restorative sleep complaints.

Sleep hygiene refers to behavioral and environmental practices that support quality sleep — consistent sleep timing, dark and cool bedroom, avoiding alcohol and caffeine close to bedtime, and limiting screens before sleep. Sleep hygiene is foundational alongside any pharmacologic treatment for menopausal insomnia.

Slow-wave sleep, also called N3 or deep sleep, is the deepest stage of non-REM sleep, characterized by delta waves on EEG. It supports memory consolidation, growth hormone release, immune function, and physical recovery. Bedtime oral micronized progesterone enhances slow-wave sleep through its allopregnanolone metabolite.

Spironolactone is a potassium-sparing diuretic with antiandrogenic activity, used off-label for female pattern hair loss, hirsutism, and acne. Doses of 50–200 mg daily are typical for these uses. It is not a menopause-specific drug but addresses common androgen-related midlife complaints.

Steady state is the condition in which drug input (dosing) equals drug elimination, producing stable average plasma concentration. It is reached after roughly 4–5 half-lives of regular dosing. Hormone therapy reaches steady state within days to a couple weeks of starting most regimens.

STRAW+10 (Stages of Reproductive Aging Workshop +10) is the international consensus staging system for the menopause transition. It defines 10 stages from late reproductive years through postmenopause based on cycle patterns and supported by hormone markers (FSH, AMH, inhibin B). It is the standard staging framework in research and specialist practice.

Stress urinary incontinence is involuntary urine leakage triggered by physical activity that increases intra-abdominal pressure — coughing, sneezing, laughing, jumping, lifting. It results from inadequate urethral support or sphincter weakness, often related to vaginal childbirth and worsened by postmenopausal tissue changes.

Stroke risk on HRT depends heavily on age and route. Oral estrogen modestly raises ischemic stroke risk in older women starting HRT after age 60; transdermal estrogen at standard doses does not significantly raise stroke risk in observational studies. The timing hypothesis applies to stroke as it does to other cardiovascular outcomes.

Subclinical hypothyroidism is elevated TSH with normal free T4. It is more common in midlife women than overt hypothyroidism. Treatment is debated: most guidelines recommend levothyroxine when TSH is persistently >10 mIU/L or when symptoms are significant and TSH is between 4.5 and 10.

Surgical menopause is menopause caused by surgical removal of both ovaries (bilateral oophorectomy). Symptoms begin within hours to days, are typically more abrupt and severe than natural menopause, and are accompanied by a sharp drop in testosterone as well as estradiol. Women under 45 with surgical menopause almost always need HRT.

The Study of Women's Health Across the Nation (SWAN) is a multi-ethnic longitudinal cohort study following more than 3,000 US women through the menopause transition. SWAN data underlie much of what is known about symptom duration, ethnic differences, and the natural history of menopause in diverse populations.

A T-score is the bone mineral density measurement on a DEXA scan compared to the mean of healthy young adults of the same sex, expressed in standard deviations. A T-score ≥ -1.0 is normal, -1.0 to -2.5 is osteopenia, and ≤ -2.5 is osteoporosis. T-scores are the primary diagnostic measure used in postmenopausal women.

Tamoxifen is a SERM used for endocrine therapy of hormone-receptor-positive breast cancer in both premenopausal and postmenopausal women. It blocks estrogen at breast tissue but acts as a partial agonist at the endometrium (small endometrial cancer risk) and bone. Hot flashes are a near-universal side effect.

Telehealth HRT is hormone replacement therapy prescribed and managed online through licensed clinicians using asynchronous (questionnaire-based) or synchronous (video) visits. It allows access to evidence-based HRT for women anywhere in the United States, often at lower cost and with shorter wait times than in-person specialty care.

Testosterone is an androgen produced in small amounts by the ovaries and adrenal glands in women throughout life. It contributes to libido, energy, and mood. There is no FDA-approved testosterone product for women in the United States; clinicians who prescribe testosterone for postmenopausal hypoactive sexual desire disorder typically use a small fraction of a male testosterone product off-label.

The Menopause Society — formerly the North American Menopause Society (NAMS) — is the leading professional society for menopause clinicians in North America, founded in 1989. It produces position statements, clinical guidelines, and the NCMP (Certified Menopause Practitioner) credential.

T4 is the principal hormone produced by the thyroid gland and a precursor to the more active T3. Free T4 measurement complements TSH in evaluating thyroid function. Levothyroxine — synthetic T4 — is the standard treatment for hypothyroidism and is one of the most-prescribed drugs in the United States.

The timing hypothesis is the concept — supported by re-analyses of the WHI and subsequent trials — that hormone replacement therapy provides the most favorable risk-benefit balance when started in younger postmenopausal women, generally under age 60 or within 10 years of the final menstrual period. Initiation outside this window has a less favorable profile.

Transdermal HRT delivers estrogen through the skin via patch, gel, spray, or body cream. Because it bypasses first-pass hepatic metabolism, transdermal estrogen does not increase venous thromboembolism risk to the degree oral estrogen does. Most modern menopause guidelines prefer transdermal estradiol as a first-line systemic estrogen.

Transdermal absorption is the passage of a drug across the skin into systemic circulation. For estradiol, transdermal delivery achieves clinically effective plasma levels with much lower input doses than oral, while bypassing first-pass hepatic metabolism. Skin temperature, hydration, and application site affect absorption rates.

T3 is the more biologically active thyroid hormone, produced both by the thyroid gland and by deiodination of T4 in peripheral tissues. T3 acts on nuclear thyroid hormone receptors to regulate metabolism, body temperature, and cardiovascular function. T3 is generally not the first-line thyroid lab in screening — TSH is — but free T3 can clarify equivocal cases.

TSH is a pituitary hormone that stimulates the thyroid gland to produce thyroxine (T4) and triiodothyronine (T3). TSH is the most sensitive screening test for thyroid dysfunction. Hypothyroidism is common in midlife women and produces symptoms — fatigue, weight gain, brain fog, mood changes — that overlap closely with menopause, so TSH should be checked in any menopause workup.

Urge urinary incontinence is involuntary urine leakage preceded by a sudden, strong urge to urinate. It is the leakage component of overactive bladder. Prevalence rises after menopause, and treatment includes behavioral therapy, vaginal estrogen, anticholinergic medications, and beta-3 agonists.

Urinary incontinence is involuntary urine leakage. The two main types are stress incontinence (leakage with cough, sneeze, exertion) and urge incontinence (leakage with sudden urgency). Both increase in prevalence after menopause. Vaginal estrogen helps urge symptoms; pelvic floor PT and other treatments address the underlying mechanism.

The urogenital tract refers to the combined reproductive and lower urinary structures — vulva, vagina, urethra, bladder trigone — that share embryologic origins and estrogen receptor expression. Genitourinary syndrome of menopause affects this entire region, which is why vaginal estrogen helps both vaginal and urinary symptoms.

USP <795> is the United States Pharmacopeia standard for non-sterile compounding. It defines requirements for facility, equipment, personnel training, ingredient quality, beyond-use dating, and documentation for compounded medications that do not require sterility (e.g., capsules, creams, ointments).

USP <797> is the United States Pharmacopeia standard for sterile compounding — preparations that must be sterile (injections, infusions, sterile vaginal preparations). It defines clean-room requirements, personnel garbing and training, environmental monitoring, and beyond-use dating for sterile compounded products.

Uterine fibroids are benign smooth-muscle tumors of the myometrium. They are highly common (50–80% of women by age 50), often estrogen-responsive, and tend to grow during the reproductive years and shrink after menopause. They can cause heavy bleeding, pelvic pressure, and pain.

The uterus is the muscular reproductive organ in which a fetus develops during pregnancy. It consists of the inner endometrium (cyclically shed during menstruation), the muscular myometrium, and the outer serosa. Estrogen drives endometrial proliferation; progesterone produces the secretory phase that supports implantation or sheds in menstruation.

Vaginal dryness is one of the most common menopausal symptoms, caused by estrogen withdrawal that thins the vaginal epithelium and reduces secretions. It manifests as dryness, burning, itching, and painful sex. The older medical term was vulvovaginal atrophy or atrophic vaginitis; modern terminology folds it into genitourinary syndrome of menopause.

The vaginal epithelium is the stratified squamous lining of the vagina, normally rich in estrogen receptors. Premenopausal estrogen maintains a thick, glycogen-rich epithelium that supports lactobacillus colonization and acidic vaginal pH. Estrogen withdrawal at menopause thins the epithelium, depletes glycogen and lactobacilli, and raises pH — the basis of GSM.

Vaginal estrogen delivers low-dose estrogen directly to the vaginal and lower urinary tract tissues to treat genitourinary syndrome of menopause. Available as creams, tablets, inserts, and rings, it produces minimal systemic absorption — much lower than systemic HRT — making it suitable for many women who cannot take systemic estrogen.

Vaginal estrogen cream is a low-dose estrogen preparation applied intravaginally with an applicator, typically nightly for 1–2 weeks then 2–3 times weekly for maintenance. The two main products are estradiol cream (Estrace) and conjugated equine estrogens cream (Premarin Vaginal Cream). Cream is dose-flexible and can also be applied externally to the vulva.

Vaginal estrogen tablets (Vagifem, Yuvafem) are small estradiol-containing tablets inserted into the vagina with an applicator. Standard dosing is one tablet daily for 2 weeks then twice weekly for maintenance. Tablets produce very low systemic absorption — among the lowest of vaginal estrogen options.

Vaginismus is involuntary tightening of the pelvic floor muscles around the vaginal opening, making penetration painful or impossible. It can be primary (lifelong) or secondary (developed later, often after a painful experience or in association with menopausal GSM). Treatment combines pelvic floor physical therapy, dilator therapy, and addressing any contributing causes.

Vasomotor symptoms (VMS) is the formal medical term for hot flashes and night sweats — episodes of sudden vasodilation and sweating triggered by hypothalamic thermoregulatory dysfunction in the setting of estrogen withdrawal. VMS affects up to 80% of menopausal women and is the most common reason women seek treatment.

Venlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI) used off-label for vasomotor symptoms. At 37.5–75 mg/day, it reduces hot flash frequency by roughly 50% in randomized trials, making it one of the more effective non-hormonal options. It is particularly useful for women on tamoxifen, since unlike paroxetine it does not significantly inhibit CYP2D6.

Visceral adiposity is fat stored within the abdominal cavity around internal organs, distinct from subcutaneous fat under the skin. It is more metabolically active, secretes inflammatory cytokines, and contributes to cardiovascular and diabetes risk. Postmenopausal estrogen withdrawal shifts fat distribution toward visceral storage.

Vitamin D is a fat-soluble nutrient and prohormone essential for calcium absorption, bone health, and immune function. Deficiency is common in midlife women and contributes to osteoporosis, fall risk, and possibly mood symptoms. Standard supplementation in menopause is 800–2000 IU daily.

Venous thromboembolism (VTE) is the formation of blood clots in deep veins (deep vein thrombosis, DVT) that can break off and lodge in the lungs (pulmonary embolism, PE). Oral estrogen modestly raises VTE risk by inducing hepatic synthesis of clotting factors; transdermal estrogen does not raise VTE risk meaningfully.

The Women's Health Initiative was a large NIH-funded randomized trial of postmenopausal women that produced the 2002 headlines that scared a generation off HRT. Re-analyses since show the risks were modest, age- and route-dependent, and largely tied to specific oral CEE+MPA combinations in older women — with much more favorable outcomes when HRT is started in the timing window.

WHIMS was the cognitive substudy of the WHI that examined dementia and cognitive decline in women aged 65+ starting HRT for the first time. It found increased dementia risk in this older subgroup on oral CEE+MPA — a finding that does not generalize to younger women starting HRT in the timing window.

A Z-score is a bone mineral density measurement on a DEXA scan compared to the mean of age- and sex-matched peers, expressed in standard deviations. Z-scores are primarily used in premenopausal women, men under 50, and children. A Z-score below -2.0 prompts evaluation for secondary causes of bone loss.